Genaissance Pharma 2Q Loss 12c/Shr Vs 26c
DOW JONES NEWSWIRES
August 9, 2005 9:43 a.m.
WASHINGTON (Dow Jones)--The following table is a summary of Genaissance Pharmaceuticals Inc.'s (GNSC) financial information for its second quarter ended June 30, as disclosed in the company's quarterly report filed Tuesday with the Securities and Exchange Commission.
2nd Quar June 30:
2005 2004
Revenue $5,030,000 $5,355,000
Net income (4,186,000) (6,777,000)
Net income
attributable to
common shareholders (4,324,000) (7,761,000)
Avg shrs (diluted) 34,677,000 30,073,000
Shr erns
Net income (.12) (.26)
Figures in parentheses are losses.
Genaissance Pharmaceuticals, based in New Haven, Conn., develops products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. |
